Whereas the primary driver of AbbVie’s $8.7bn acquisition of Cerevel, the schizophrenia candidate emraclidine, has been a disappointment, the pharma racked up a third positive Phase III readout for the first-in-class Parkinson’s disease candidate tavapadon on 9 December. Now, AbbVie says it intends to file tavapadon for US Food and Drug Administration approval in 2025.
AbbVie Logs Another Phase III Success With Tavapadon In Parkinson’s
The firm said it will file the D1/D5 dopamine receptor agonist for US FDA approval in 2025. The drug may salvage value from AbbVie’s Cerevel buyout.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from Therapy Areas
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.